IVD China last week: Sansure and Tencent Health, Dynamiker, Maxim Biotechnologies and BGI Tech, Haier Biomedical

Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare

On May 9, Sansure Biotech signed a strategic cooperation agreement with Tencent Health at Tencent’s Shanghai Binjiang headquarters. The partnership will focus on primary healthcare scenarios, aiming to jointly build a “patient full-cycle management platform” centered on rapid diagnostics and AI-driven private domain operations, assisting primary clinics in transitioning from traditional “single-treatment points” to comprehensive “family full-cycle health management centers.”

Research indicates that many primary clinics experience adult patient repurchase rates below 15%, with medication adherence rates as low as 50%. The lack of a long-term patient management system leaves clinics in a persistent “traffic anxiety” dilemma. To address this, Sansure Biotech and Tencent Health are jointly launching the AI Ecosystem.

Dynamiker Expands to Singapore

On May 8, Dynamiker announced an external investment initiative. In line with its strategic layout and business development needs, the company’s wholly-owned subsidiary, JiYun (Zhuhai) Biotechnology Co., Ltd., has invested its own funds to establish a sub-subsidiary in Singapore, with a registered capital of USD 20,000. The newly established company, PHOEBE BIOTECHNOLOGY PTE. LTD., is registered at Paya Lebar Square, Singapore, and its business scope includes wholesale trade of various goods without a leading product and other holding company activities.

Dynamiker is a high-tech joint-stock biopharmaceutical company dedicated to the research, development, production, and sales of innovative in vitro diagnostic products for invasive fungal diseases (IFD) and other pathogenic microorganisms. In Q1 2026, the company reported revenue of CNY 54.04 million, with net profit attributable to shareholders of CNY 18.32 million.

Maxim Biotechnologies and BGI Tech Forge Strategic Partnership to Build a New Pathology Industry Ecosystem

Recently, Maxim Biotechnologies and BGI Tech officially reached a strategic cooperation agreement. Based on a shared vision for the innovative development of precise tumor diagnostics, both parties will leverage their respective technological expertise and core strengths within the industry chain to establish a strategic partnership, building a deeply collaborative pathology industry ecosystem. Together, they aim to promote the standardization of multiplex immunofluorescence technology and its clinical translation, driving high-quality development in precision oncology.

The collaboration will focus on BGI Tech’s PMIF-20 pathology slide staining and scanning system, utilizing Maxim Biotechnologies’s expertise in core pathological reagents and consumables to accelerate the adaptation and deployment of the PMIF-20 platform in diverse application scenarios. Additionally, by leveraging BGI Tech’s global supply chain and channel network, the partners will promote Maxin Biotech’s immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) products internationally, strengthening their competitive advantage in the global pathology field and advancing human health through technological innovation.

Haier Biomedical Receives Recognition from Euromonitor International

On May 7, global market research authority Euromonitor International released data recognizing Haier Biomedical as No.1 in sales among Chinese independent brands for both domestic and overseas life sciences laboratory equipment. In the ultra-low temperature preservation sector, Haier Biomedical’s self-developed Eco-Drive Ultra-Green technology increases energy efficiency by 30% over the industry’s highest standards and ranks among the top eight recipients of the US UL “Energy Star” certification. In 2025, Haier Biotech’s overseas revenue exceeded CNY 843 million, with a year-on-year growth of 17.94%.